Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.32 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (b-cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 40 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1154
Sealed predictions
- FCRL2 in dopamine neurons, braak+0.41 (p 0.269) → +0.58 (p 0.102)receipt 1160
Swarm cases
receipt 1160: FCRL2 in dopamine neurons, braak
- power
- full sample +0.48 (p 0.043, n 18), 95% CI +0.02 to +0.77. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.45 (p 0.060, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.41 (p 0.091, n 18). could be the mix.
- skeptic
- leave-one-out range +0.43 to +0.67, sign flips 0; without severely affected donors +0.48 (p 0.043, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FCRL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts